Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model: A comparison of different dosage regimens including a pharmacokinetically enhanced formulation

Clinical Microbiology and Infection

Volumn 8, Issue 10, 2002, Pages 646-653

  Lowdin E ^a   Cars, O ^a   Odenholt, I ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Amoxicillin clavulanic acid; Dosing regimens; H. influenzae; In vitro kinetic model; Pharmacodynamics

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAMASE; CLAVULANIC ACID;

ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DILUTION; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; INOCULATION; MEMBRANE FILTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; SIMULATION; STATISTICAL SIGNIFICANCE;

BACTERIA (MICROORGANISMS); HAEMOPHILUS INFLUENZAE;

EID: 0036805581     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0691.2002.00441.x     Document Type: Article

References (13)

1. Eagle H, Fleischman R, Musselman AD. Effect of schedule of administration on the therapeutic efficacy of penicillin. Am J Med 1950; 9: 280-99.
2. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. J Pediatr Infect Dis 1996; 15: 255-9.
3. Craig WA. Pharmacokinetic/Pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-12.
4. Dagan R, Klugman KP, Craig WA, Baquero F. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J Antimicrob Chemother 2001; 47: 129-40.
5. Todd PA, Benfield P. Amoxicillin/clavulanic acid: an update of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1990; 39: 264-307.
6. Kaye C, Allen A, Perry S et al. The clinical pharmacokinetics of a new pharmacokinetically enhanced amoxicillin/Clavulanic acid formulation. Clin Therapeut 2001; 23: 578-84.
7. Cars O, Henning C, Holm SE. Penetration of ampicillin and dicloxacillin into tissue cage fluid in rabbits: Relation to serum and tissue protein binding. Scand J Infect Dis 1981; 13: 69-74.
8. Löwdin E, Odenholt I, Bengtsson S, Cars O. Pharmacodynamic effects of sub-MICs of benzyl-penicillin against Streptococcus pyogenes in a newly developed in vitro kinetic model. Antimicrob Agents Chemother 1996; 40: 2478-82.
9. Löwdin E, Odenholt I, Cars O. In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 1998; 42: 2739-44.
10. Vogelman B, Gudmundsson S, Turnidge J, Legget J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 158: 831-47.
11. Cars O. Efficacy of beta-lactam antibiotics: integration of pharmacokinetics and pharmacodynamics. Diagn Microbiol Infect Dis 1997; 27: 29-33.
12. Andes D, Craig WA. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother 1998; 42: 2375-9.
13. Thorburn CE, Moleworth SJ, Sutherland R, Rittenhouse S. Postantibiotic and post β-lactamase inhibitor effect of amoxicillin plus clavulanate. Antimicrob Agents Chemother 1996; 40: 2796-2801.